Compounds

Compound Namesort ascending Developer(s)
Xanthones
Whole-Cell Hit-to-Lead
Whole cell pathway screens
Whole Cell Hit-to Lead
Whole cell fragment screens
Vitamin D3 The Aurum Institute NPC
Ureas
Tryptanthrins
Trisubstituted benzimidazoles
TL1 Inhibitors
Thioridazine
TGF-B inhib +Cox 2 inhibitor
Telacebec (Q203) Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
TBI-223 TB Alliance, Institute of Materia Medica
TBI-166 Institute of Materia Medica, CAMS & PUMC
TBAJ-876 Diarylquinoline TB Alliance, University of Auckland
TBAJ-587, Diarylquinoline TB Alliance, University of Auckland, Merck & Co., Inc.
TBA-7371 TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research
TBA-354 TB Alliance
TB-47 Guangzhou Egg Biotechnology Co., Ltd.
TB Respiratory Chain CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson
Sutezolid Sequella, Inc, TB Alliance
Sulfolane GlaxoSmithKline
SQ641
SQ609 Sequella, Inc
SQ109 Sequella, Inc
SPR720 Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
SPR-113
Spectinamide 1810 Microbiotix, Inc.
SATB-082 Sanofi, TB Alliance
Sanfetrinem GlaxoSmithKline, Bill & Melinda Gates Foundation
S-004992 Shionogi & Co., Ltd
Ruthenium (II) phosphine/diimine/picolinate complexes
RNA Polymerase Inhibitors
Rifapentine CDC TBTC, Sanofi
Rifapentine
Rifampicin St. George's Hospital University of London
Rifampicin PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Rifabutin
Quinolone TBK-613
Pyridomycin
Pyrazinamide Analogs
Pyrazidamide TB Alliance
Protein Splicing Inhibitors
Pretomanid TB Alliance
PKS13 Inhibitors - TAM16
PKS13 Inhibitors - Coumestan Derivatives
Phenotypic Hit-to-Lead
Optimized Background Regimen (OBR)
OPC-167832 Otsuka Pharmaceutical Development & Commercialization, Inc.
Novel hit-lead programs
Nitazoxanide Weill Medical College of Cornell University
Mycobacterial Gyrase Inhibitors
MTopo
Moxifloxacin for Drug-Sensitive TB
Moxifloxacin TB Alliance
Meropenem / Clavulanate
Menaquinone Synthase Inhibitors
Malate Synthase Inhibitors
Macrolides
Macozinone (MCZ, PBTZ-169) iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Macozinone (MCZ, PBTZ-169) Nearmedic Plus LLC
Levofloxacin CDC TBTC, NIAID, NIH, DHHS, Boston University
LeuRS inhibitors GlaxoSmithKline, Anacor Pharmaceuticals
Isoniazid
Inhibitors of isoprenoid biosynthesis
Inhibitors of DosRST signaling and persistence Michigan State University
InhA Inhibitor GSK-693
Indoles
Indolcarboxamides TB Alliance
Indazoles GlaxoSmithKline, TB Alliance
Indazole sulfonamide GSK 724 (DG167) GlaxoSmithKline, Rutgers, The State University of New Jersey
IMPDH Inosine monophosphate dehydrogenase inhibitors
Immunoxel
Hsp65 DNA
HMG-CoA Reductase Inhibitors
HE2000
GyrB Inhibitors
Gyrase B Inhibitor
GSK839 GlaxoSmithKline
GSK839 GlaxoSmithKline
GSK-286 GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
GSK 3036656 GlaxoSmithKline, European Union Horizon 2020, NIAID, NIH, DHHS
Gatifloxacin
Folate Biosynthesis Inhibitors
Faropenem WBA
Everolimus The Aurum Institute NPC
Energy Metabolism Inhibitors
EMB
DprE1 Inhibitors Calibr, The Scripps Research Institute
DprE Inhibitors
DNA metabolism
Delpazolid (LCB01-0371) LegoChem Biosciences, Inc.
Delamanid Otsuka Pharmaceutical Development & Commercialization, Inc.
DC-159a
Cyclopeptides
CPZEN-45
Contezolid (MRX-4/MRX-1) MicuRx Pharmaceuticals, Inc.
Clofazimine Novartis
Celecoxib WBA
Celecoxib
CC-11050 The Aurum Institute NPC
BTZ-043 University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
BRD4592 The Broad Institute
Bortezomib SPRINT TB (National University of Singapore)
Bi-functional Molecules
Benzofuroxan São Paulo State University (UNESP)
Bedaquiline Janssen Research & Development, LLC
AZD5847 AstraZeneca
Auranofin The Aurum Institute NPC, Calibr, The Scripps Research Institute
ATP Synthesis Inhibitors TB Alliance, University of Auckland
Amidino-urea 8918 Weill Medical College of Cornell University, NIAID, NIH, DHHS
Adamantanids
Actinomycete metabolites
2HRZE 2HR
1599 Microbiotix, Inc.